Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update

Jason H. Karnes; Allan E. Rettie; Andrew A. Somogyi; Rachel Huddart; Alison E. Fohner; Christine M. Formea; Ming Ta Michael Lee; Adrian Llerena; Michelle Whirl-Carrillo; Teri E. Klein; Elizabeth J. Phillips; Scott Mintzer; Andrea Gaedigk; Kelly E. Caudle; John T. Callaghan

doi:10.1002/cpt.2008

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update

Jason H. Karnes, Allan E. Rettie, Andrew A. Somogyi, Rachel Huddart, Alison E. Fohner, Christine M. Formea, Ming Ta Michael Lee, Adrian Llerena, Michelle Whirl-Carrillo, Teri E. Klein, Elizabeth J. Phillips, Scott Mintzer, Andrea Gaedigk, Kelly E. Caudle, John T. Callaghan

Research output: Contribution to journal › Review article › peer-review

101 Scopus citations

Abstract

Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org).

Original language	English (US)
Pages (from-to)	302-309
Number of pages	8
Journal	Clinical Pharmacology and Therapeutics
Volume	109
Issue number	2
DOIs	https://doi.org/10.1002/cpt.2008
State	Published - Feb 2021

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1002/cpt.2008

Cite this

Karnes, J. H., Rettie, A. E., Somogyi, A. A., Huddart, R., Fohner, A. E., Formea, C. M., Ta Michael Lee, M., Llerena, A., Whirl-Carrillo, M., Klein, T. E., Phillips, E. J., Mintzer, S., Gaedigk, A., Caudle, K. E., & Callaghan, J. T. (2021). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clinical Pharmacology and Therapeutics, 109(2), 302-309. https://doi.org/10.1002/cpt.2008

Karnes, JH, Rettie, AE, Somogyi, AA, Huddart, R, Fohner, AE, Formea, CM, Ta Michael Lee, M, Llerena, A, Whirl-Carrillo, M, Klein, TE, Phillips, EJ, Mintzer, S, Gaedigk, A, Caudle, KE & Callaghan, JT 2021, 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update', Clinical Pharmacology and Therapeutics, vol. 109, no. 2, pp. 302-309. https://doi.org/10.1002/cpt.2008

@article{527b5e6a4dc34adb8fac83509a98d1a6,

title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update",

abstract = "Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org).",

author = "Karnes, {Jason H.} and Rettie, {Allan E.} and Somogyi, {Andrew A.} and Rachel Huddart and Fohner, {Alison E.} and Formea, {Christine M.} and {Ta Michael Lee}, Ming and Adrian Llerena and Michelle Whirl-Carrillo and Klein, {Teri E.} and Phillips, {Elizabeth J.} and Scott Mintzer and Andrea Gaedigk and Caudle, {Kelly E.} and Callaghan, {John T.}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors Clinical Pharmacology & Therapeutics {\textcopyright} 2020 American Society for Clinical Pharmacology and Therapeutics",

year = "2021",

month = feb,

doi = "10.1002/cpt.2008",

language = "English (US)",

volume = "109",

pages = "302--309",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing

T2 - 2020 Update

AU - Karnes, Jason H.

AU - Rettie, Allan E.

AU - Somogyi, Andrew A.

AU - Huddart, Rachel

AU - Fohner, Alison E.

AU - Formea, Christine M.

AU - Ta Michael Lee, Ming

AU - Llerena, Adrian

AU - Whirl-Carrillo, Michelle

AU - Klein, Teri E.

AU - Phillips, Elizabeth J.

AU - Mintzer, Scott

AU - Gaedigk, Andrea

AU - Caudle, Kelly E.

AU - Callaghan, John T.

PY - 2021/2

Y1 - 2021/2

N2 - Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org).

AB - Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org).

UR - http://www.scopus.com/inward/record.url?scp=85090156780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090156780&partnerID=8YFLogxK

U2 - 10.1002/cpt.2008

DO - 10.1002/cpt.2008

M3 - Review article

C2 - 32779747

AN - SCOPUS:85090156780

SN - 0009-9236

VL - 109

SP - 302

EP - 309

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 2

ER -

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this